Field Trip Health CEO talks psychedelics industry, IPO plans

Field Trip Health Ltd. (OTCMKTS: FTRPF) executive chairman and co-founder Ronan Levy and the company’s special adviser, Tom Daschle, a former United States senator, were on CNBC to discuss the future of the psychedelics industry and the company.

What does the company do?

Field Trip develops and delivers psychedelic therapies and it has centres across North America and Europe.

According to the CEO, the company currently focuses on psilocybin, MDMA, DMT, LSD and some next generation molecules. The company has two divisions — Field Trip Discovery division and Field Trip Health division. Expanding on the Discovery division, he said:

While drawing the difference with conventional pharma and explaining the second division, he added:

Field Trip has filed to go public on NASDAQ

In a press release earlier today, Field Trip announced that it has applied to list its common shares on the NASDAQ stock market.

Field Trip will continue to trade on the Toronto Stock Exchange under the symbol “FTRP”. It trades in the in the United States on the OTC market (OTCQX) under the symbol "FTRPF" and will continue to be quoted there until its shares are listed on the NASDAQ.

A real paradigm shift is underway with regard to research and science on psychedelics

Daschle believes that there is a real paradigm shift that is underway right now with regard to research and science. People are also becoming more aware of the capacity of psychedelics to address mental health issues.

He also thinks we are recovering from misinformation that has occurred for decades around these therapies in the past and added: